The Molecular Imaging Probes and Contrast Agents Database (MICAD), created at the National Center for Biotechnology Information, National Institutes of Health via the PubMed/MedLine databases and other sources, has added 17 new agents, increasing the total to 841 agents in the database.
The new PET agents are:
- 64Cu-PEI which targets heparin sulfate proteoglycans;
- [11C]Methoxy-Sch225336 which targets cannabinoid CB2 receptor (CB2R);
- [11C]SU11274 which targets mesenchymal-epithelial transition factor (MET); and
- [11C]SL25.1188 which targets monoamine oxidase B (MAO-B).
The new SPECT agents are:
- 67Ga-DOTA-GlyGlu-CycMSH which targets melanocortin-1 receptor (MC1R);
- [186Re]MAMA-HBP and [186Re]MAMA-BP which both targets farnesyl disphosphate (pyrophosphate) synthase;
- [125I]IodoDPA-713 which targets peripheral-type benzodiazepine receptor (PBR), also known as translocator protein (TSPO);
- [125I]-BH-Exendin(9-39) which targets glucagon-like peptide-1 (GLP-1) receptor;
- 125I-EGFR-Fab which targets epidermal growth factor receptor (EGFR);
- 111In-[DTPA1-Lys3,Tyr4]-BN which targets gastrin-releasing peptide receptor (GRPR);
- 111In-DOTA-E3-uroguanylin which targets receptor guanylate cyclase C (GC-C);
- 99mTc-PR81 which targets mucin; and
- 99mTc-DTPA-TOR which targets estrogen receptor.
The new optical agents are:
- tAB50-Cy5 which targets caspase-3 and caspase-7;
- Legumain probe 1 which targets legumain/asparaginyl endopeptidase; and
- AnxB12 Cys101,Cys260-IANBD which targets phosphatidylserine.